MA41140A - Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg - Google Patents
Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la pargInfo
- Publication number
- MA41140A MA41140A MA041140A MA41140A MA41140A MA 41140 A MA41140 A MA 41140A MA 041140 A MA041140 A MA 041140A MA 41140 A MA41140 A MA 41140A MA 41140 A MA41140 A MA 41140A
- Authority
- MA
- Morocco
- Prior art keywords
- quinazoline
- dioxo
- sulfonamide derivatives
- parg inhibitors
- parg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201422098 | 2014-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41140A true MA41140A (fr) | 2017-10-17 |
Family
ID=54937266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041140A MA41140A (fr) | 2014-12-12 | 2015-12-10 | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
Country Status (15)
Country | Link |
---|---|
US (1) | US10239843B2 (fr) |
EP (1) | EP3230273A1 (fr) |
JP (1) | JP2017537137A (fr) |
KR (1) | KR20170093967A (fr) |
CN (1) | CN107207467A (fr) |
AU (1) | AU2015359082A1 (fr) |
BR (1) | BR112017012402A2 (fr) |
CA (1) | CA2969296A1 (fr) |
IL (1) | IL252575A0 (fr) |
MA (1) | MA41140A (fr) |
MX (1) | MX2017007478A (fr) |
RU (1) | RU2017124425A (fr) |
SG (1) | SG11201704686UA (fr) |
WO (1) | WO2016092326A1 (fr) |
ZA (1) | ZA201704382B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
WO2016169906A1 (fr) | 2015-04-21 | 2016-10-27 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de 2,4-dioxo-1,2-dihydropyrido[3,4-d]pyrimidine |
CA3205780A1 (fr) | 2020-12-24 | 2022-06-30 | Modulus Discovery, Inc. | Compose de tetrahydrothienopyridinesulfonamide |
CA3225500A1 (fr) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Composes inhibiteurs de parg |
WO2023057394A1 (fr) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | Dérivés de n,n-diméthyl-4-(7-(n-(1-méthylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)pipérazine-1-carboxamide et dérivés correspondants de pyrazolo[1,5-a]pyridine utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer |
WO2023154913A1 (fr) * | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | Inhibiteurs de parg |
WO2023165571A1 (fr) * | 2022-03-04 | 2023-09-07 | 上海璎黎药业有限公司 | Composé contenant une structure cyclique hétéroaromatique à cinq chaînons, composition pharmaceutique et utilisation associées |
WO2023175184A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer |
WO2023175185A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer |
TW202400597A (zh) * | 2022-04-28 | 2024-01-01 | 大陸商北京丹擎醫藥科技有限公司 | 三環雜環衍生物,其組合物和應用 |
US11939335B2 (en) | 2022-05-17 | 2024-03-26 | 858 Therapeutics, Inc. | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG |
WO2023224998A1 (fr) * | 2022-05-17 | 2023-11-23 | 858 Therapeutics, Inc. | Inhibiteurs de parg |
WO2024017306A1 (fr) * | 2022-07-19 | 2024-01-25 | 苏州信诺维医药科技股份有限公司 | Composé cyclique hétéroaromatique contenant du soufre, composition pharmaceutique de celui-ci et son utilisation |
EP4311829A1 (fr) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Dérivés d'hétéroaryl sulfonamide bicyclique substitués pour le traitement du cancer |
WO2024074497A1 (fr) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Composé inhibiteur de parg |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1157858A (fr) * | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Derives de quinazoline |
DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
US7009052B2 (en) * | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
SI1719773T1 (sl) | 2004-02-24 | 2009-08-31 | Japan Tobacco Inc | Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
WO2007014226A2 (fr) * | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Composes pour le traitement de neurodegenerescence et d'accident cerebro-vasculaire |
MY146494A (en) | 2006-01-24 | 2012-08-15 | Lilly Co Eli | Indole sulfonamide modulators of progesterone receptors |
JP2009530342A (ja) | 2006-03-20 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Btkおよびsyk蛋白キナーゼを阻害する方法 |
US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
CN102089302A (zh) | 2008-07-17 | 2011-06-08 | 旭化成制药株式会社 | 含氮二环性杂环化合物 |
CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
EP2566328B1 (fr) | 2010-05-07 | 2015-03-04 | GlaxoSmithKline LLC | Indazoles |
ES2552977T3 (es) | 2010-05-07 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolinas como inhibidores de quinasa |
CN103108871B (zh) * | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
EA026115B1 (ru) * | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение |
EP2471363A1 (fr) * | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes |
WO2013027168A1 (fr) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine |
WO2013067300A1 (fr) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Méthode de traitement |
JP2014106019A (ja) | 2012-11-26 | 2014-06-09 | Stack Electronics Co Ltd | プローブ |
KR101942151B1 (ko) | 2012-12-27 | 2019-01-24 | 드렉셀유니버시티 | Hbv 감염에 대한 항바이러스 물질 |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
-
2015
- 2015-12-10 MA MA041140A patent/MA41140A/fr unknown
- 2015-12-11 JP JP2017531303A patent/JP2017537137A/ja active Pending
- 2015-12-11 AU AU2015359082A patent/AU2015359082A1/en not_active Abandoned
- 2015-12-11 KR KR1020177019260A patent/KR20170093967A/ko unknown
- 2015-12-11 WO PCT/GB2015/053883 patent/WO2016092326A1/fr active Application Filing
- 2015-12-11 MX MX2017007478A patent/MX2017007478A/es unknown
- 2015-12-11 EP EP15813508.7A patent/EP3230273A1/fr not_active Withdrawn
- 2015-12-11 US US15/533,804 patent/US10239843B2/en active Active
- 2015-12-11 CN CN201580075728.3A patent/CN107207467A/zh active Pending
- 2015-12-11 SG SG11201704686UA patent/SG11201704686UA/en unknown
- 2015-12-11 RU RU2017124425A patent/RU2017124425A/ru not_active Application Discontinuation
- 2015-12-11 CA CA2969296A patent/CA2969296A1/fr not_active Abandoned
- 2015-12-11 BR BR112017012402A patent/BR112017012402A2/pt not_active Application Discontinuation
-
2017
- 2017-05-29 IL IL252575A patent/IL252575A0/en unknown
- 2017-06-28 ZA ZA2017/04382A patent/ZA201704382B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017537137A (ja) | 2017-12-14 |
CN107207467A (zh) | 2017-09-26 |
IL252575A0 (en) | 2017-07-31 |
ZA201704382B (en) | 2019-09-25 |
US10239843B2 (en) | 2019-03-26 |
KR20170093967A (ko) | 2017-08-16 |
WO2016092326A1 (fr) | 2016-06-16 |
BR112017012402A2 (pt) | 2017-12-26 |
CA2969296A1 (fr) | 2016-06-16 |
EP3230273A1 (fr) | 2017-10-18 |
SG11201704686UA (en) | 2017-07-28 |
AU2015359082A1 (en) | 2017-06-29 |
RU2017124425A (ru) | 2019-01-14 |
MX2017007478A (es) | 2018-05-04 |
US20180016242A1 (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
BR112017023853A2 (pt) | composições de nanopartícula para terapia sustentada. | |
MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
DK3319956T3 (da) | Substituerede oxopyridinderivater | |
IL255266A0 (en) | Amino-disubstituted cyclohexane histories | |
DK3302448T3 (da) | Erstattede heterocyclylafledninger som cdk-inhibitore | |
MA53352A (fr) | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase | |
DK3094631T3 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
HRP20181698T1 (hr) | 2-amino-6-(difluormetil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridini kao inhibitori bace1 | |
DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
DK3286177T3 (da) | Quinolinderivater som tam rtk-inhibitorer | |
CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
DK3319597T3 (da) | Sammensætninger, der omfatter antistof-duocarmycin-lægemiddelkonjugater | |
IL250038A0 (en) | 4,5 - dehydroisoxazole derivatives used as nampt inhibitors | |
MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
HK1257565A1 (zh) | 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物 | |
IL260011B (en) | History of water-soluble 5,3-diphenyldiazole compounds | |
HK1257567A1 (zh) | 作為htra1抑制劑的新型二氟酮酰胺衍生物 | |
DK3389633T3 (da) | Farmaceutiske sammensætninger, der omfatter phenylaminopyrimidinderivat |